Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600
S&P Dow Jones Indices said Krystal Biotech (KRYS) will move from the S&P SmallCap 600 to the S&P MidCap 400, replacing Taylor Morrison Home (TMHC). Tutor Perini (TPC) will replace Krystal Biotech in the SmallCap 600. Berkshire Hathaway (BRK.A/BRK.B) is acquiring Taylor Morrison. V2X (VVX) will replace Avanos Medical (AVNS) in the SmallCap 600 as American Industrial Partners’ acquisition is expected to close soon.
How this was made
The 30-second read
Why it matters
The primary tradable element is passive index rebalancing around the stated effective dates, with additional deal-related uncertainty for TMHC and AVNS.
Market read
Traders should monitor order-flow and spreads around index reconstitution dates, and separately track deal-close expectations for TMHC and AVNS.
What to watch
Liquidity and borrow availability for the removed constituents (TMHC, AVNS) could matter more than the index change itself, especially if deal-arb positioning is already crowded.
Background
S&P Dow Jones Indices announced scheduled constituent changes to the S&P MidCap 400 and S&P SmallCap 600, with specific effective dates tied to pending acquisitions.
Ticker impact
Krystal Biotech will move from S&P SmallCap 600 to S&P MidCap 400, effective before July 24 open, due to index rebalancing.
Likely modest, event-driven price pressure into the effective date, then mean reversion after reconstitution.
The article is a PRNewswire index-change notice with defined effective dates, but no fundamentals or deal economics for KRYS are disclosed.
Taylor Morrison Home will be removed from S&P MidCap 400 effective before July 24 open, as Berkshire Hathaway acquires it.
Potential volatility around July 24 as index funds rebalance and deal expectations update.
The notice ties TMHC’s index change to a pending Berkshire acquisition, but provides no deal price or closing certainty beyond 'expected to close'.
Tutor Perini will replace Krystal Biotech in the S&P SmallCap 600 effective before July 24 open, creating reconstitution flows.
Possible short-term bid into the effective date, followed by normalization after reconstitution.
The article specifies the replacement mechanics and timing but does not include any company-specific operational news.
V2X will replace Avanos Medical in the S&P SmallCap 600 effective before July 27 open, per S&P Dow Jones Indices.
Modest event-driven move possible into July 27, with reduced impact afterward.
This is a pure index methodology change with a clear effective date, without additional fundamentals.
Avanos Medical will be removed from the S&P SmallCap 600 effective before July 27 open as American Industrial Partners acquires it.
Potential volatility into the effective date as passive selling overlaps with deal positioning.
The article links AVNS’s index exit to an acquisition 'expected to close soon' but omits deal terms and timing precision.
Market effects
Reconstitution flows may temporarily affect small-cap and mid-cap biotech/industrial names, but no sector-wide fundamental change is described.
Primarily US passive-fund flow impact; no cross-region effects mentioned.
Limited global relevance, as the event is US index methodology and US-listed constituents.
Counterpoint
Because these are index-only changes, any price impact may be largely anticipated by systematic traders and could be muted versus deal-driven names (TMHC, AVNS).
Key entities
- companyKrystal Biotech Inc.
Moves from S&P SmallCap 600 to S&P MidCap 400 effective before July 24 open.
- companyTaylor Morrison Home Corp.
Replaced in S&P MidCap 400 effective before July 24 open; acquisition by Berkshire Hathaway expected to close around then.
- companyTutor Perini Corp.
Replaces Krystal Biotech in S&P SmallCap 600 effective before July 24 open.
- companyV2X Inc.
Replaces Avanos Medical in S&P SmallCap 600 effective before July 27 open.
- companyAvanos Medical Inc.
Replaced in S&P SmallCap 600 effective before July 27 open; acquisition by American Industrial Partners expected to close soon.
